share_log

Earnings Call Summary | Biolase(BIOL.US) Q1 2024 Earnings Conference

Earnings Call Summary | Biolase(BIOL.US) Q1 2024 Earnings Conference

業績電話會議摘要 | Biolase (BIOL.US) 2024 年第一季度業績會議
富途資訊 ·  05/14 17:15  · 電話會議

The following is a summary of the BIOLASE, Inc. (BIOL) Q1 2024 Earnings Call Transcript:

以下是BIOLASE, Inc.(BIOL)2024年第一季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • BIOLASE reported a significant growth in consumable sales, marking a 14% increase compared to the same quarter last year, making it one of the strongest quarters in the company's history.

  • The company achieved a reduction in its adjusted EBITDA loss by 21%, demonstrating improved financial discipline and operational efficiency.

  • The CEO, John Beaver, expressed optimism towards achieving profitability by the end of the year.

  • BIOLASE ended the first quarter with a cash balance of $6.4 million and expects to report positive adjusted EBITDA for the full year of 2024.

  • BIOLASE報告稱,消耗品銷售大幅增長,與去年同期相比增長了14%,成爲該公司歷史上最強勁的季度之一。

  • 該公司調整後的息稅折舊攤銷前利潤虧損減少了21%,這表明財務紀律和運營效率得到改善。

  • 首席執行官約翰·比弗對年底之前實現盈利表示樂觀。

  • BIOLASE在第一季度末的現金餘額爲640萬美元,預計2024年全年調整後的息稅折舊攤銷前利潤將爲正數。

Business Progress:

業務進展:

  • A significant portion of BIOLASE's U.S. Waterlase sales (67%) for the quarter was to new customers, with dental specialists accounting for about 42% of these sales.

  • The company organized and participated in over a hundred promotional events, ranging from webinars to trade shows, aimed at promoting the benefits of laser dentistry.

  • BIOLASE continued to roll out their unique Waterlase and EPIC academy training programs.

  • The company's ongoing commercial focus remains on reaching to the estimated 90% of dentists who are yet to adopt all-tissue laser technology.

  • In the future, the company plans to allocate investments towards revenue-generating activities.

  • For 2024, BIOLASE has projected a year-over-year revenue growth ranging from 6% to 8%, translating to an estimated full year revenue of between $52 million to $53 million.

  • BIOLASE本季度美國Waterlase銷售額的很大一部分(67%)來自新客戶,牙科專家約佔這些銷售額的42%。

  • 該公司組織並參與了一百多場促銷活動,從網絡研討會到貿易展覽會,旨在宣傳激光牙科的好處。

  • BIOLASE繼續推出其獨特的Waterlase和EPIC學院培訓計劃。

  • 該公司持續的商業重點仍然是向尚未採用全組織激光技術的估計90%的牙醫提供服務。

  • 將來,該公司計劃將投資分配給創收活動。

  • BIOLASE預計2024年的收入同比增長6%至8%不等,這意味着全年收入估計在5200萬美元至5300萬美元之間。

More details: Biolase IR

更多詳情: Biolase IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論